Maria N. Jure-Kunkel

Person

Plainsboro, NJ, US

People

Patents Grantslast 30 patents

Information Patent Grant
PD-L1 binding polypeptides for imaging
- Patent number 12,194,110
- Issue date Jan 14, 2025
- Bristol-Myers Squibb Company
- Paul E. Morin
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Bispecific antibodies against CD3 and CD20 for treating chronic lym...
- Patent number 11,858,995
- Issue date Jan 2, 2024
- GENMAB A/S
- Brian Elliott
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Bispecific antibody against CD3 and CD20 in combination therapy for...
- Patent number 11,845,805
- Issue date Dec 19, 2023
- GENMAB A/S
- Brian Elliott
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Bispecific antibody against CD3 and CD20 in combination therapy for...
- Patent number 11,608,383
- Issue date Mar 21, 2023
- GENMAB A/S
- Brian Elliott
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Antibodies against CD73 and uses thereof
- Patent number 11,352,440
- Issue date Jun 7, 2022
- Bristol-Myers Squibb Company
- Nils Lonberg
- G01 - MEASURING TESTING
Information Patent Grant
PET imaging with PD-L1 binding polypeptides
- Patent number 11,344,639
- Issue date May 31, 2022
- Bristol-Myers Squibb Company
- Paul E. Morin
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
PD-L1 binding polypeptides for imaging
- Patent number 11,173,219
- Issue date Nov 16, 2021
- Bristol-Myers Squibb Company
- Paul E. Morin
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
- Patent number 11,103,579
- Issue date Aug 31, 2021
- Bristol-Myers Squibb Company
- Bryan Barnhart
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,604,575
- Issue date Mar 31, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,584,170
- Issue date Mar 10, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,577,423
- Issue date Mar 3, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
PD-L1 binding polypeptides for imaging
- Patent number 10,406,251
- Issue date Sep 10, 2019
- Bristol-Myers Squibb Company
- Paul E. Morin
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,323,092
- Issue date Jun 18, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,323,093
- Issue date Jun 18, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,316,091
- Issue date Jun 11, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,316,090
- Issue date Jun 11, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,308,714
- Issue date Jun 4, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- G01 - MEASURING TESTING
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,596
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,594
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,595
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Antibodies against CD73
- Patent number 10,167,343
- Issue date Jan 1, 2019
- Bristol-Myers Squibb Company
- Nils Lonberg
- G01 - MEASURING TESTING
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,138,299
- Issue date Nov 27, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Antibodies against CD73 and uses thereof
- Patent number 10,100,129
- Issue date Oct 16, 2018
- Bristol-Myers Squibb Company
- Nils Lonberg
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,072,082
- Issue date Sep 11, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 9,856,320
- Issue date Jan 2, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Antibodies against CD73
- Patent number 9,605,080
- Issue date Mar 28, 2017
- Bristol-Myers Squibb Company
- Nils Lonberg
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fully human antibodies against human 4-1BB
- Patent number 9,382,328
- Issue date Jul 5, 2016
- Bristol-Myers Squibb Company
- Maria Jure-Kunkel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Combination of anti-CTLA4 antibody with diverse therapeutic regimen...
- Patent number 9,320,811
- Issue date Apr 26, 2016
- Bristol-Myers Squibb Company
- Maria Jure-Kunkel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Antibodies that bind PD-L1 and uses thereof
- Patent number 9,212,224
- Issue date Dec 15, 2015
- Bristol-Myers Squibb Company
- John Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fully human antibodies against human 4-1BB
- Patent number 8,716,452
- Issue date May 6, 2014
- Bristol-Myers Squibb Company
- Maria Jure-Kunkel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION...
- Publication number 20250002600
- Publication date Jan 2, 2025
- GENMAB A/S
- Alexander MUIK
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240417471
- Publication date Dec 19, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION...
- Publication number 20240409653
- Publication date Dec 12, 2024
- GENMAB A/S
- Alexander MUIK
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS
- Publication number 20240262924
- Publication date Aug 8, 2024
- GENMAB A/S
- Ugur SAHIN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTIBODY AND TAXANE COMBINATION THERAPY
- Publication number 20240109972
- Publication date Apr 4, 2024
- GENMAB A/S
- Ugur SAHIN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240034793
- Publication date Feb 1, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- G01 - MEASURING TESTING
Information Patent Application
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR...
- Publication number 20240034812
- Publication date Feb 1, 2024
- GENMAB A/S
- Brian Elliott
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240002512
- Publication date Jan 4, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR...
- Publication number 20230312758
- Publication date Oct 5, 2023
- Brian ELLIOTT
- C07 - ORGANIC CHEMISTRY
Information Patent Application
BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYM...
- Publication number 20230312757
- Publication date Oct 5, 2023
- GENMAB A/S
- Brian ELLIOTT
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTIBODIES FOR USE IN THERAPY
- Publication number 20230087164
- Publication date Mar 23, 2023
- GENMAB A/S
- Ugur SAHIN
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTIBODIES AGAINST CD73 AND USES THEREOF
- Publication number 20230051701
- Publication date Feb 16, 2023
- Bristol-Myers Squibb Company
- Nils LONBERG
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TREATMENT OF RENAL CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIB...
- Publication number 20220389110
- Publication date Dec 8, 2022
- Bristol-Myers Squibb Company
- Maria JURE-KUNKEL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PET IMAGING WITH PD-L1 BINDING POLYPEPTIDES
- Publication number 20220347324
- Publication date Nov 3, 2022
- Bristol-Myers Squibb Company
- Paul E. MORIN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR...
- Publication number 20220144964
- Publication date May 12, 2022
- GENMAB A/S
- Brian Elliott
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR...
- Publication number 20220119544
- Publication date Apr 21, 2022
- GENMAB A/S
- Brian Elliott
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYM...
- Publication number 20220112287
- Publication date Apr 14, 2022
- GENMAB A/S
- Brian Elliott
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION OF DR5 AGONIST AND ANTI-PD-1 ANTAGONIST AND METHODS OF USE
- Publication number 20220098302
- Publication date Mar 31, 2022
- Bristol-Myers Squibb Company
- Bryan Barnhart
- C07 - ORGANIC CHEMISTRY
Information Patent Application
NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING
- Publication number 20220001040
- Publication date Jan 6, 2022
- Bristol-Myers Squibb Company
- Paul E. MORIN
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20200308282
- Publication date Oct 1, 2020
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AN...
- Publication number 20190382491
- Publication date Dec 19, 2019
- Bristol-Myers Squibb Company
- Maria JURE-KUNKEL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING
- Publication number 20190343972
- Publication date Nov 14, 2019
- Bristol-Myers Squibb Company
- Paul E. MORIN
- C07 - ORGANIC CHEMISTRY
Information Patent Application
COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES
- Publication number 20190284293
- Publication date Sep 19, 2019
- Bristol-Myers Squibb Company
- Nils LONBERG
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TREATMENT OF RENAL CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIB...
- Publication number 20190263923
- Publication date Aug 29, 2019
- Bristol-Myers Squibb Company
- Maria JURE-KUNKEL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PET IMAGING WITH PD-L1 BINDING POLYPEPTIDES
- Publication number 20190184042
- Publication date Jun 20, 2019
- Bristol-Myers Squibb Company
- Paul E. MORIN
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190153099
- Publication date May 23, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190135920
- Publication date May 9, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190112377
- Publication date Apr 18, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190112376
- Publication date Apr 18, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190100589
- Publication date Apr 4, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Maria N. Jure-Kunkel

Person

Patents Grantslast 30 patents

PD-L1 binding polypeptides for imaging

Bispecific antibodies against CD3 and CD20 for treating chronic lym...

Bispecific antibody against CD3 and CD20 in combination therapy for...

Bispecific antibody against CD3 and CD20 in combination therapy for...

Antibodies against CD73 and uses thereof

PET imaging with PD-L1 binding polypeptides

PD-L1 binding polypeptides for imaging

Combination of DR5 agonist and anti-PD-1 antagonist and methods of use

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

PD-L1 binding polypeptides for imaging

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Antibodies against CD73

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Antibodies against CD73 and uses thereof

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Antibodies against CD73

Fully human antibodies against human 4-1BB

Combination of anti-CTLA4 antibody with diverse therapeutic regimen...

Antibodies that bind PD-L1 and uses thereof

Fully human antibodies against human 4-1BB

Patents Applicationslast 30 patents

MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION...

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION...

COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS

ANTIBODY AND TAXANE COMBINATION THERAPY

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR...

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR...

BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYM...

ANTIBODIES FOR USE IN THERAPY

ANTIBODIES AGAINST CD73 AND USES THEREOF

TREATMENT OF RENAL CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIB...

PET IMAGING WITH PD-L1 BINDING POLYPEPTIDES

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR...

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR...

BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYM...

COMBINATION OF DR5 AGONIST AND ANTI-PD-1 ANTAGONIST AND METHODS OF USE

NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AN...

NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING

COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES

TREATMENT OF RENAL CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIB...

PET IMAGING WITH PD-L1 BINDING POLYPEPTIDES

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING